GSA Capital Partners LLP Buys New Stake in Exagen Inc. $XGN

GSA Capital Partners LLP acquired a new stake in shares of Exagen Inc. (NASDAQ:XGN) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 214,721 shares of the company’s stock, valued at approximately $998,000.

A number of other institutional investors also recently bought and sold shares of the stock. Bridgeway Capital Management LLC lifted its stake in shares of Exagen by 10.3% during the second quarter. Bridgeway Capital Management LLC now owns 27,800 shares of the company’s stock worth $194,000 after buying an additional 2,600 shares during the period. Truvestments Capital LLC lifted its holdings in shares of Exagen by 109.5% in the 4th quarter. Truvestments Capital LLC now owns 6,169 shares of the company’s stock valued at $38,000 after buying an additional 3,225 shares during the period. State Street Corp lifted its holdings in Exagen by 6.9% in the fourth quarter. State Street Corp now owns 71,256 shares of the company’s stock valued at $433,000 after acquiring an additional 4,600 shares during the period. Acadian Asset Management LLC acquired a new position in shares of Exagen in the 1st quarter valued at $25,000. Finally, Russell Investments Group Ltd. boosted its stake in shares of Exagen by 3.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 229,115 shares of the company’s stock worth $2,518,000 after acquiring an additional 8,499 shares in the last quarter. 75.25% of the stock is currently owned by institutional investors and hedge funds.

Exagen Trading Up 0.6%

XGN opened at $6.70 on Tuesday. Exagen Inc. has a 12 month low of $2.59 and a 12 month high of $12.23. The stock has a market capitalization of $162.34 million, a price-to-earnings ratio of -8.27 and a beta of 2.05. The company has a debt-to-equity ratio of 1.96, a current ratio of 3.18 and a quick ratio of 3.18. The business has a fifty day moving average price of $4.95 and a 200 day moving average price of $3.97.

Exagen (NASDAQ:XGN) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.06. Exagen had a negative net margin of 26.61% and a negative return on equity of 104.46%. The firm had revenue of $19.94 million for the quarter, compared to analysts’ expectations of $17.80 million. Sell-side analysts expect that Exagen Inc. will post -0.67 earnings per share for the current fiscal year.

Analyst Ratings Changes

XGN has been the topic of a number of recent analyst reports. B. Riley Financial reiterated a “buy” rating and set a $12.00 target price (up from $8.00) on shares of Exagen in a research report on Wednesday, August 5th. Roth Capital began coverage on shares of Exagen in a research note on Wednesday, June 24th. They issued a “buy” rating and a $8.00 target price on the stock. Wall Street Zen raised shares of Exagen from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Canaccord Genuity Group decreased their price objective on Exagen from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Finally, TD Cowen increased their target price on shares of Exagen from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $9.62.

Exagen Company Profile

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.